Blood
Articles in this Issue
Everybody gets a CAR! But do they need it?
A WHIM of the marrow: myelokathexis as a cytological clue to a rare blood disorder
Clonal dynamics of CH in CLL
Timing is everything: the CAR T-cell clock is ticking
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia
Abstract Chronic lymphocytic leukemia (CLL) and clonal hematopoiesis (CH) both commonly occur in older individuals. To characterize CH in CLL, 620 patients were analyzed (CLL12 [ib...
Lipid nanotubes unmask neutrophils for complement attack
Abstract Neutrophils, critical components of innate immunity, undergo significant morphological changes during phagocytosis. In this study, we demonstrate that neutrophils exposed...
How can we safely eliminate RT in pediatric HL?
Nanotube vesicles: a new neutrophil inflammatory response
Introduction to a review series on the new wave of targeted therapeutics for MPNs
Ruxolitinib and subsequent JAK2 inhibitors have improved care for some patients with the myeloproliferative neoplasms myelofibrosis, essential thrombocythemia (ET), and polycythemia vera, but major pr...
Catch them ALL?
Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms
Abstract Janus kinase (JAK) inhibitors have changed the treatment landscape of myeloproliferative neoplasms (MPNs), graft-versus-host disease, and several autoimmune conditions. Al...
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
Abstract Circadian rhythms orchestrate immune activation and effector function, yet whether within-day timing influences chimeric antigen receptor (CAR) T-cell therapy outcomes rem...
Outcomes of BCP-ALL with hypodiploidy or <i>BCR</i> :: <i>ABL1</i> fusion in children undergoing allogeneic HSCT: results from the FORUM study
Abstract Hypodiploid and BCR::ABL1+ B-cell precursor acute lymphoblastic leukemia (BCP-ALL) confers a high risk of disease relapse. We investigated post–hematopoietic stem cell tra...
Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis
Abstract The discovery of calreticulin (CALR) mutations in patients with myeloproliferative neoplasms (MPNs) has paved the way for the elucidation of a unique disease mechanism tha...
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3
Abstract Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed/refractory (R/R) mantle c...
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Abstract Immune checkpoint inhibitor–associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence,...
Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis
Abstract The peptide hepcidin is produced by the liver and serves as the central negative regulator of iron trafficking. Recently, drugs that affect the hepcidin pathway have been...
HOD08 for low-risk pediatric Hodgkin lymphoma
Platelets in the crossfire of immune checkpoint therapy
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08
Abstract The Pediatric Hodgkin Consortium hypothesized that by increasing chemotherapeutic dose density for Hodgkin lymphoma (HL) they could increase the complete response (CR) rat...